Clinical trials

6

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Feasibility of Web-based Therapy Sessions

The goal of this feasibility study is to explore rehabilitation outcomes, usability and user experience of a web-based platform for delivering treatment for cognitive and language impairment amongst adults with acquired neurological disorders in critical illness and stroke disorders. The main question it aims to answer is: " Is it feasible to use a web-based platform for delivering rehabilitation treatment in a large acute National Health Care Organisation" Participants will undergo therapy sessions prescribed by therapists on a web-based platform instead of the conventional paper-based therapy sessions for their cognitive and speech rehabilitation needs.

Participants needed: 80
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Liverpool University Hospitals NHS Foundation TrustUpdated: May 1, 2026Locations: 1
Eligibility criteria

Patients with cognitive impairment and/or speech impairment being treated at the... [+1]

Inability to obtain consent [+5]

Status: Not yet recruiting

Achilles Tendon Rupture Patient Outcomes at 12 Months

The Achilles tendon is the strongest and largest tendon in the human body, playing a critical role in plantarflexion and facilitating activities such as walking, running, and jumping. However, it is also the most frequently ruptured tendon. The injury and associated disability have a significant impact on patient quality of life and healthcare services. Achilles tendon ruptures are increasingly common, particularly among middle-aged recreational athletes, with an incidence estimated at 18 per 100,000 person-years. The Swansea Morriston Achilles Rupture Treatment (SMART) protocol represents a structured, progressive approach to non-operative rehabilitation. It emphasizes early mobilization, protected weight-bearing, and a gradual return to sport or high-level function through targeted strength and neuromuscular training. While short-term outcomes of non-surgical protocols have demonstrated promising results, there remains limited high-quality data on long-term isokinetic strength and patient-reported functional outcomes beyond six months in this patient group. This study aims to evaluate isokinetic plantarflexor strength and self-reported functional outcomes at 12 months following non-surgical management of Achilles tendon ruptures using the SMART rehabilitation protocol. By assessing both objective and subjective recovery metrics, we aim to contribute to the growing evidence base for evidence-informed, conservative Achilles tendon rehabilitation. A secondary aim of the study is to examine the relationship between isokinetic strength scores and self reported functional recovery scores using the ATRS questionnaire. Participants will attend one 60-90 minute visit to complete a short questionnaire and perform a safe, clinic-based ankle strength test using an isokinetic machine; the test feels like pushing against a footplate, similar to resisted ankle movements. The results of these tests will be collected and analysed. The study will help to gain further insight into patient recovery from this injury.

Participants needed: 115
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Liverpool University Hospitals NHS Foundation TrustUpdated: Mar 3, 2026Locations: 2
Eligibility criteria

Adults aged 18 years or older at the time of recruitment. [+4]

Unable to provide informed consent. [+5]

Status: Not yet recruiting

Air Tamponade Versus Fluorinated Gas Tamponade for Rhegmatogenous Retinal Detachment

TITLE: RCT of air tamponade versus fluorinated gas tamponade for rhegmatogenous retinal detachment DESIGN: Non-inferiority RCT of 150 patients from 10 UK centres AIMS: To assess whether air tamponade is non inferior to gas tamponade for the repair of RRD treated with vitrectomy. PRIMARY OUTCOME MEASURE: Primary anatomical success with single operation at 24 weeks.

Participants needed: 150
Trial details
Age: 40+Biological sex: AllType: InterventionalSponsor: Liverpool University Hospitals NHS Foundation TrustUpdated: Dec 24, 2025
Eligibility criteria

Primary uncomplicated RRD undergoing vitrectomy. [+2]

Absence of PVD [+13]

Status: Not yet recruiting

Safety, Tolerability and Performance of the NucleoCapture Extracorporeal Therapeutic Apheresis Device in the Reduction of Circulating cfDNA/NETs in Subjects With Pancreatitis

This is a single-centre, randomised-controlled, open-label, feasibility study to assess the safety, tolerability and performance of the NucleoCapture extracorporeal apheresis device in the reduction of circulating cell-free DNA (cfDNA)/Neutrophil Extracellular Traps (NETs) in patients with severe acute pancreatitis.

Participants needed: 20
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Liverpool University Hospitals NHS Foundation TrustUpdated: Mar 20, 2025Locations: 1
Eligibility criteria

Adult patients aged 18 or over [+4]

The use of other non-routine extracorporeal treatments such as very high flux re... [+24]

Status: Recruiting

Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients

The purpose of this study is to assess a new test to detect antibodies which may form following kidney transplant. These antibodies can be difficult to detect as they do not cause any symptoms but can lead to kidney damage. A new blood test will be performed alongside existing antibody tests to see how well the test functions in comparison and to see how well it is able to distinguish between inflammation caused by antibodies and other sorts of inflammation such as a urinary tract infection. The investigators also want to determine whether it is predictable whom will develop antibodies after a transplant and use these results to change the current way patients are monitored for antibodies after receiving a transplant. In addition to this, the investigators want to establish if patients over 60 years of age are relatively protected against immunological events such as rejection compared to patients who are under 60 years of age. The results could potentially lead to using a different immunosuppression regime based on which population age group patients belong to and lowering the risks associated with these drugs.

Participants needed: 282
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Liverpool University Hospitals NHS Foundation TrustUpdated: Aug 30, 2024Locations: 1
Eligibility criteria

Adult patients transplanted within 6-12 months (retrospective recruitment) [+5]

Transplanted for longer than 12 months; [+7]

Status: Not yet recruiting

Novel Cardiovascular Biomarkers in Patients With Kidney Disease

Chronic kidney disease (CKD) is a long-term condition where the kidneys do not work as well as they should. End-stage kidney failure (ESKD) is the final, irreparable stage of chronic kidney disease (CKD), where kidney function has worsened, so the kidneys can no longer function independently. At this stage, dialysis is required to remove waste products and excess fluid from the blood. There are two types of dialysis. In haemodialysis (HD), blood is pumped out of the body to an artificial kidney machine and returned to the body by tubes that connect a person to the machine. In peritoneal dialysis (PD), the inside lining of the belly acts as a natural filter. PD has the advantage of being gentler on the heart. HD causes significant stress to the heart by reducing the blood flow to the heart muscle, resulting in heart failure, irregular rhythms, and eventually sudden heart death. A large observational study showed that HD patients had 48% worse survival in the first two years than PD patients. Several molecules ('biomarkers') can be detected in blood and inform doctors of heart damage. Studying the form and function of proteins (Proteomics), including how they work and interact with each other inside cells in patients, could help identify the onset of heart problems. HD patients are also prone to body fat changes (cholesterol/lipids). Due to high cholesterol, there is build-up on the walls of arteries, causing their hardening. In HD patients, this process is faster due to abnormalities in lipid structure. Therefore, studying the heart biomarkers, protein, and lipid makeup of HD patients may help to find people at substantial risk of heart and vascular problems and if they are likely to become unwell due to these heart problems.

Participants needed: 100
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Liverpool University Hospitals NHS Foundation TrustUpdated: Sep 18, 2023
Eligibility criteria

Patients with pre-existing heart disease will be excluded. [+1]